Gilead And Macrogenics Announce Oncology Collaboration To Develop Bispecific Antibodies
By, Admin1 min read
Share
Gilead Sciences, Inc., And Macrogenics Today Announced An Exclusive Option And Collaboration Agreement To Develop Mgd024, An Investigational, Bispecific Antibody That Binds Cd123 And Cd3 Using Macrogenics
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
